Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Scandinavian Journal of Infectious Diseases|June 18, 2013
Latent tuberculosis among injection drug users in a methadone maintenance treatment program, Taipei, Taiwan: TSPOT.TB versus tuberculin skin testYung-Feng Yen, Bor-Shen Hu, Yu-Shiuan Lin, et al.
The Journal of Pathology|February 19, 2015
Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burdenMichael S Anglesio, Ali Bashashati, Yi Kan Wang, et al.
BMC Cancer|May 20, 2015
Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasmsRobertson Mackenzie, Stefan Kommoss, Boris J Winterhoff, et al.
The Journal of Pathology|March 8, 2011
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomasMelissa K McConechy, Michael S Anglesio, Steve E Kalloger, et al.
The Journal of Pathology|June 2, 2012
Use of mutation profiles to refine the classification of endometrial carcinomasMelissa K McConechy, Jiarui Ding, Maggie Cu Cheang, et al.
Cancer Research|July 26, 2023
Biallelic Dicer1 Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of DICER1 Syndrome-Associated CancerYemin Wang, Shary Yuting Chen, Monica Ta, et al.
ACS Chemical Biology|April 24, 2024
mRNA Display Identifies Potent, Paralog-Selective Peptidic Ligands for ARID1BGregor S Cremosnik, Yannick Mesrouze, Patrik Zueger, et al.
Neoplasia (New York, N.Y.)|September 18, 2025
Proteomic analysis uncovers biological diversity in molecularly defined endometrial carcinomasDawn R Cochrane, Gian Luca Negri, Jutta Huvila, et al.
The Journal of Pathology|June 20, 2013
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profilingAli Bashashati, Gavin Ha, Alicia Tone, et al.
The Journal of Pathology|August 18, 2012
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomasMichael S Anglesio, Stefan Kommoss, Mary C Tolcher, et al.
Pageof 7